FDA Releases List of Genetic Variants Known to Affect Existing Drug Therapies
The FDA believes it has sufficient scientific evidence to suggest certain genetic variants are likely to have altered the metabolism of many drugs, and in certain cases, result in different therapeutic results, including a difference in risk of adverse events.
Co-Diagnostics Seeks CE Mark for its COVID-19 Coronavirus Test
The test uses the company’s CoPrimer technology to detect the presence of ribonucleic acid (RNA) of the novel strain of coronavirus in a real-time RT-PCR kit that targets conserved regions in the virus genome.
![ArcherDX said its Archer Immunoverse and VariantPlex NGS assays will be used by Ambry toward offering its biopharma customers large-scale immune repertoire analysis and chimeric antigen T-cell receptor (CAR-T) manufacturing characterization and pharmacodynamics. [royaltystockphoto/Getty Images]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1550-218x150.jpeg "Researchers Discover Molecular Pathway Involved in Immunotherapy Response")
Researchers Discover Molecular Pathway Involved in Immunotherapy Response
A newly discovered pathway that detects DNA in the cytoplasm and triggers inflammation and cellular senescence, may be modulated during senescence-inducing chemotherapy to affect cancer cell response to checkpoint inhibitors.
Map of Human Thymus Gland May Suggest New Immune Therapies
The researchers used single cell technology to isolate and analyze around 200,000 individual cells from the developing thymus to record which genes were active in each individual cell and used those genes as tags to map each cell to its exact location in the thymus.
Precision Molecular Nabs Investment from ADDF for Development of More Effective Neuroinflammation Imaging Agents
The company’s radiotracer, PMI04, binds the macrophage colony stimulating factor 1 receptor (CSF1R) which, in the brain, is found almost exclusively on microglia and infiltrating macrophages, cell types directly involved in inflammation.
Researchers Detail Mechanism for Clearing Misfolded Proteins at Root of Alzheimer’s Disease
The chaperone protein Clusterin shuttles misfolded proteins directly into cells for degradation, a finding that could point to new therapeutic targets for AD and other neurodegenerative diseases.
![One of the major scientific crusades in oncology has been to identify and validate biomarkers associated with recurrent breast cancer. [iStock / royaltystockphoto]](https://www.clinicalomics.com/wp-content/uploads/2019/01/585-218x150.jpeg "Agendia Reports Positive Results in IMPACt Trial for Breast Cancer")
Agendia Reports Positive Results in IMPACt Trial for Breast Cancer
MammaPrint and BluePrint reclassified 40% of pathologically subtyped tumors, highlighting the need for an individualized, molecular subtyping profile in early stage breast cancer diagnosing for patients.
Detailed Map of Breast Cancer Reveals the Effects of Mutations on the Tumor Landscape
The maps detail the intricacies and complexity of the breast cancer landscape—comprising cancer cells, immune cells and connective tissue—and how it varies both between, and within, tumors depending on their unique genetic makeup.
![Berg will partner with Massachusetts General Hospital and Brigham and Women's Hospital to study potential biomarkers for Alzheimer's and other neurodegenerative disorders from Harvard Biomarker Study biospecimens. [Source: ajcity.net]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1397-218x150.jpeg "Protein that Prevents Tau Clearance Linked to AD and Other Tau Tangle Proteinopathies")
Protein that Prevents Tau Clearance Linked to AD and Other Tau Tangle Proteinopathies
The researchers found that a protein known as β-arrestin2 increases the accumulation of the neurotoxic tau tangles that cause several forms of dementia, by interfering with the process that cells use to remove excess tau from the brain.
PRS Only Marginally Better than Established Methods of Predicting Heart Disease
While the results showed a strong association between polygenic risk scores and CHD, with those scoring highest on this calculator at baseline most likely to experience cardiac events over the follow-up period, the results were roughly the same using the ACC/AHA calculator.
